{
  "docId": "019de075-3cec-7700-94db-076a5ce30d84",
  "docSlug": "8c2d629a90974743be7d15f16a23e50f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 56,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Uses historical peer data (Morphic, Prometheus) to project value inflection points for SPY001.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3cec-7700-94db-076a5ce30d84/27",
  "deckHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84",
  "deckJsonHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84.json",
  "deckAnchorHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.38,
        "y": 0.245
      },
      "kind": "callout",
      "text": "Morphic oral α4β7: Value at Phase 1 data",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63cd35a0-da66-4487-9ece-61ffcd915135",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.68,
        "y": 0.16
      },
      "kind": "callout",
      "text": "Further step-up in value with induction Phase 2 data",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed6302f5-0d5e-49a5-89a9-3b780b8d5c03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.92,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "chart",
      "text": "Market cap comps at key events: Projected",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d5c47c2-e942-45d2-8a4d-5bcf4035b0e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.32,
        "w": 0.96,
        "x": 0.02,
        "y": 0.58
      },
      "kind": "diagram",
      "text": "Projected 2023, 2024, 2025+ timeline with SPY001 clinical phases",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4ed9449-08f6-477d-b9a4-7c4c103ee019",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.12,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: FactSet 30-d average market caps after event date. 1 Morphic Phase 2a single arm UC data; Prometheus RCT (UC) and single arm (CD) Phase 2.; Prometheus ultimately acquired for $10.8B after Phase 2 data",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e49f791-610c-4eff-8700-0614e8638947",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Key value inflection in ~18 months with Phase 1 PK data anticipated to validate SPY001 as “long-acting Vedo”",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4359a66f-889e-4fb9-b0e6-e6b85ad23766",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Slide recipe: the peer-gap chart",
      "slug": "peer-gap-chart-recipe",
      "agent": "designer",
      "layer": "slide",
      "matchId": "8fdaaf4e-219c-406e-8580-d42854a76124",
      "evidence": "chart/bar-grouped: Market cap comps at key events: Projected",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "fcf1c03d-fc0b-4e3d-b38d-e934d3fd3681",
      "evidence": "The slide uses a horizontal timeline to map clinical milestones to projected value inflection points.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 30,
      "from": 13,
      "beatId": "5fcb9464-3068-4031-9434-ce301bbe9fd3",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents the company's solution, including its pipeline and strategy",
      "position": 3,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 13,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "1d2b0809-4269-4aea-a725-b67c9452d570",
      "evidence": "The document presents the company's solution, including its pipeline and strategy",
      "position": 2,
      "objective": "What is the company's solution?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.8,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}